These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
261 related items for PubMed ID: 26223933
21. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma]. Wang J, Liu LT, Cui D, He L, Liu DG. Zhonghua Bing Li Xue Za Zhi; 2019 Apr 08; 48(4):288-292. PubMed ID: 30955264 [Abstract] [Full Text] [Related]
22. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L. Eur J Endocrinol; 2013 May 08; 168(5):675-81. PubMed ID: 23416953 [Abstract] [Full Text] [Related]
23. BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Chen Y, Sadow PM, Suh H, Lee KE, Choi JY, Suh YJ, Wang TS, Lubitz CC. Thyroid; 2016 Feb 08; 26(2):248-55. PubMed ID: 26671072 [Abstract] [Full Text] [Related]
24. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W. Ann Surg Oncol; 2009 Feb 08; 16(2):240-5. PubMed ID: 19034577 [Abstract] [Full Text] [Related]
27. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA. Pathology; 2013 Dec 08; 45(7):637-44. PubMed ID: 24247620 [Abstract] [Full Text] [Related]
30. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm. Silver JA, Bogatchenko M, Pusztaszeri M, Forest VI, Hier MP, Yang JW, Tamilia M, Payne RJ. J Otolaryngol Head Neck Surg; 2021 Nov 06; 50(1):63. PubMed ID: 34742355 [Abstract] [Full Text] [Related]
31. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F. J Clin Endocrinol Metab; 2007 Nov 06; 92(11):4085-90. PubMed ID: 17785355 [Abstract] [Full Text] [Related]
32. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Walczyk A, Kowalska A, Kowalik A, Sygut J, Wypiórkiewicz E, Chodurska R, Pięciak L, Góźdź S. Clin Endocrinol (Oxf); 2014 Jun 06; 80(6):899-904. PubMed ID: 24354346 [Abstract] [Full Text] [Related]
36. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. J Clin Endocrinol Metab; 2008 Oct 06; 93(10):3943-9. PubMed ID: 18682506 [Abstract] [Full Text] [Related]
37. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression. Kim MH, Bae JS, Lim DJ, Lee H, Jeon SR, Park GS, Jung CK. Endocr Relat Cancer; 2014 Oct 06; 21(6):891-902. PubMed ID: 25266729 [Abstract] [Full Text] [Related]
38. [Association of BRAF(V) 600E mutation with clinical pathological features in papillary thyroid carcinoma: meta-analysis]. Yan K, Lin X, Li S, Bao H, Zhao L, Liu X. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep 06; 49(9):759-64. PubMed ID: 25487587 [Abstract] [Full Text] [Related]
39. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, Chung JK, Youn YK, Kim KH, Park DJ, Cho BY. Head Neck; 2010 Jan 06; 32(1):38-45. PubMed ID: 19475551 [Abstract] [Full Text] [Related]